Overview
A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]
Indication
Indinavir is an antiretroviral drug for the treatment of HIV infection.
Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2010/02/11 | Phase 2 | Completed | Barbara Ensoli, MD, PhD | ||
2008/03/18 | Phase 2 | UNKNOWN | Oncology Institute of Southern Switzerland | ||
2006/08/10 | Phase 2 | Completed | |||
2005/09/20 | N/A | Completed | Harvard School of Public Health (HSPH) | ||
2005/09/19 | Phase 4 | Completed | |||
2005/09/12 | Phase 3 | Completed | French National Agency for Research on AIDS and Viral Hepatitis | ||
2005/07/22 | Not Applicable | Terminated | French National Agency for Research on AIDS and Viral Hepatitis | ||
2005/07/19 | Phase 2 | Terminated | French National Agency for Research on AIDS and Viral Hepatitis | ||
2003/07/11 | Phase 2 | Completed | |||
2002/12/10 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| STAT Rx USA LLC | 16590-064 | ORAL | 400 mg in 1 1 | 6/14/2012 | |
| Rebel Distributors Corp | 21695-366 | ORAL | 400 mg in 1 1 | 11/4/2008 | |
| State of Florida DOH Central Pharmacy | 53808-0661 | ORAL | 400 mg in 1 1 | 8/18/2010 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| No Health Canada approvals found for this drug. | |||||
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| CRIXIVAN 400 MG CAPSULAS DURAS | 96024005 | CÁPSULA DURA | Uso Hospitalario | Not Commercialized | |
| CRIXIVAN 200 MG CAPSULAS DURAS | 96024003 | CÁPSULA DURA | Uso Hospitalario | Not Commercialized | |
| CRIXIVAN 400 mg CAPSULAS DURAS | 96024009 | CÁPSULA DURA | Uso Hospitalario | Not Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.